TNO155
- Batoprotafib
Axon 3865
CAS:
1801765-04-7
- Optical Purity: 0.99
- Soluble in 0.1N HCl(aq) and DMSO
- MF: C18H24ClN7OS
- MW: 421.95
Description
TNO155 is a highly potent (IC50 = 11 nM), selective and orally bioavailable allosteric small-molecule inhibitor of SHP2.
More Information
| Parent CAS No. | 1801765-04-7 |
|---|---|
| Chemical Name | (3S,4S)-8-(6-Amino-5-(2-amino-3-chloropyridin-4-ylthio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine |
| extra_info | Sold in collaboration with Chemietek |
| SMILES | C1(SC2C(Cl)=C(N)N=CC=2)C(N)=NC(N2CCC3([C@H](N)[C@H](C)OC3)CC2)=CN=1 |&1:18,20,r| |
| MFCD | N.A. |
| InChi | InChI=1S/C18H24ClN7OS/c1-10-14(20)18(9-27-10)3-6-26(7-4-18)12-8-24-17(16(22)25-12)28-11-2-5-23-15(21)13(11)19/h2,5,8,10,14H,3-4,6-7,9,20H2,1H3,(H2,21,23)(H2,22,25)/t10-,14+/m0/s1 |
| InChiKey | UCJZOKGUEJUNIO-IINYFYTJSA-N |
| CID | 118238370 |
| Short Description | SHP2 inhibitor |
References
- C Liu et al. Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling. Clin Cancer Res. 2021 Jan 1;27(1):342-354.
- A Weiss et al. Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C. Cancer Discov. 2022 Jun 2;12(6):1500-1517.
Other Categories
Get a Quote for
Loading...